Publications and Presentations
Breast Cancer Prevention
Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi GN, Sneige N. Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials. Clinical Cancer Research 2007;13(16):4943-4948.
[Abstract in PubMed]
Arun B, Valero V, Yin G, Babiera G, Murray JL, Browne D, Gong G, Cook E, Hortobagyi GN, Sneige N: Phase II breast cancer chemoprevention study with celecoxib in women at increased risk for breast cancer. J Clin Oncol 24(Suppl 18S): 18s (abstract 1010), 2006.
Brown P, Arun B, Miller A : Prevention of breast cancer using rexinoids: results of a phase II biomarker modulation trial using bexarotene in women at high risk of breast cancer. Breast Cancer Res and Treat 2007; 106:S181, Abstract 4046.
Chamberlain CS, Schmetze KH, Anderson JR, Khan SA, Dooley WC, Krontiras H, Browne D, Kimler BF, Fabian CJ. High risk women report minimal pain rating score with random periareolar fine needle aspirations compared to ductal lavage.; 29th SABCS 2006.
Fabian CJ, Kimler, Anderson JR, Chamberlain C, Mayo MS, Khan SA, Dooley WC, Krontiras N, Browne D. Comparison of efficacy of Random Periareolar Fine Needle Aspiration vs. Ductal Lavage for Acquisition of Breast Tissue in Meeting eligibility Requirements for Phase II Chemoprevention Study. 29th SABCS, 2006.
Fabian CJ, Kimler BF, Anderson JR, Chamberlain C, Mayo MS, Zalles CM, O'Shaughnessy JA, Lynch HT, Johnson KA, Browne D: Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene. J Clin Oncol 24(Suppl 18S): 18s (abstract 1001), 2006.
Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano C, Cazzaniga M, Mora S, Gulisano M, Johansson H, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A: Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women. J Clin Oncol 2006; 24:129-135.
Johnson KA: The SERM of My Dreams. J Clin Endocrinol Metab 2006; 91:3754-3756.
Kim H-T, Duong S, Li Y, Uray I, DeNardo D, Hilsenbeck S, Tsimeizon A, Brown P,
Bissonnette R, Lamph W, and Johnson K: Discovery of rexinoid-modulated biomarkers in human breast cells using microarrays. Proc. American Association for Cancer Research 47:917, 2006 (Abstract #3901).
Kimler BF, Fabian CJ, Methany T, Xue Q, Zalles CM, Mayo MS, Khan SA, Dooley WC, Krontiras N, Browne D: Comparison of cytomorphology and immunocytochemistry in breast epithelial cells obtained by random periareolar fine needle aspiration vs ductal lavage. 97th Annual AACR Meeting; p 336 (abstract 1425), 2006.
Kimler BF, Ursin G, Fabian CJ, Anderson JR, Chamberlain C, Mayo MS, O'Shaughnessy JA, Lynch HT, Johnson KA, Browne D: Effect of the third generation selective estrogen receptor modulator arzoxifene on mammographic breast density. J Clin Oncol 24(Suppl 18S):18s (abstract 562), 2006.
Li Y, Hill J, Zhang Y, Kim H-T, Uray I, Bissonnette R, Lamph W, Johnson K, and Brown P: Rexinoids prevent the development of premalignant mammary lesions in MMTV-erbB2 mice. Proc. American Association for Cancer Research 47:917, 2006 (Abstract #3899).
Lord SJ, Bernstein L, Johnson K, Malone K, Weiss L, McDonald J, Ursin G: Parity, breastfeeding and breast cancer risk by hormone receptor status in women with late age at first birth - A case-control study. Proc. American Association for Cancer Research 48:622, 2007 (Abstract #2610).
Macis D, Gandini S, Johansson A, COMT V158M, mammographic density and circulating sex hormones in a randomized, double-blind 2 x 2 phase II trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. Frontiers in Cancer Prevention Research, Programs and Proceedings 2007, p152, Abstract B105.
Solzenberg-Solomon R, Chang S-C, Leitzmann M, Johnson K, Johnson C, Buys S, Hoover R, and Zeigler R: Folate Intake, Alcohol Use and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Am J Clin Nut; 2006; 83:895-904.
Fabian CJ, Kimler BF, Anderson JR, Chamberlain CS, Mayo MS, Khan SA, Dooley WC, Krontiras H, Browne D: Comparison of random periareolar fine needle aspiration vs. ductal lavage for acquisition of breast tissue in meeting eligibility requirements for a phase II chemoprevention study. Fourth Annual AACR International Conference on Frontiers in Cancer Prevention Research; p 83 (abstract A56), 2005.
Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE, O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne, D. Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, A Third Generation Selective Estrogen Receptor Modulator. Clin Cancer Res 2004: 10: 5403-5417.
Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH J, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA: A phase II breast cancer chemoprevention trial of oral difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Research 2002; 8:3105-3117.
[Abstract in PubMed]
Back to Top
Cervical Cancer Prevention
Carreon J, Sherman ME, Guillen D, Solomon D, Herrero R, et.a. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. International J Gyn Pathol 2007;26:441-446.
[Abstract in PubMed]
Castle P, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356-358.
[Abstract in PubMed]
Hildesheim A, Herrero R, Wacholder S, Rodrigues AC, Solomon D, et al. Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women with Preexisting Infection. JAMA 2007;298:743-753.
[Abstract in PubMed]
Safaeian M and Solomon D. Cervical cancer prevention – Cervical screening: Science in Evolution. In: Obstetrics and Gynecology Clinics of North America. Philadelphia, PA, Saunders: 2007.[Abstract in PubMed]
Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of Precancer and Follow-up Management Strategies for Women with HPV-Negative Atypical Squamous Cells of Undetermined Significance. Obstet Gynecol
2007;109:6:1325-31.
[Abstract in PubMed]
Solomon D, Stoler M, Jeronimo J, Khan M, Castle P, Schiffman M. Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low grade cytologic abnormalities. Obstet Gynecol 2007;110:288-295.
[Abstract in PubMed]
Walker JL, Wang SS, Schiffman M, Solomon D, for the ALTS Group. Predicting Absolute risk of CIN3 during post-colposcopic follow-up: Results from the ASCUS/LSIL Triage Study. Letter to the Editor. Am J Ob Gyn 2007 in press.
[Abstract in PubMed]
Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. For the 2006 ASCCP consensus conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340-345.
[Abstract in PubMed]
Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. For the 2006 ASCCP consensus conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-355.
[Abstract in PubMed]
Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ, for the ALTS Group. Cost Effectiveness Analysis based on the ASCUS and LSIL Triage Study. J Natl Cancer Inst 2006;98:92-100.
Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, Schiffman M, Solomon D, Jeronimo J, for the ALTS Group. Number of Cervical Biopsies and Sensitivity of Colposcopy. Obstet Gynecol 2006;108:264-272.
Walker JL, Wang SS, Schiffman M, Solomon D, for the ALTS Group. Predicting absolute risk of CIN3 during post-colposcopic follow-up: Results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol 2006;195:341-348.
Zuna RE, Wang SS, Schiffman M, Solomon D, for the ALTS Group. Comparison of HPV distribution in cytologic subgroups of Low Grade Squamous Intrraepithelial Lesion. Cancer Cytopathol 2006;108:288-297.
Sherman ME, das Gupta A, Schiffman M, Nayar R, Solomon D. Bethesda Interobserver Reproducibility Study (BIRST). Cancer Cytopathol 2007;111:15-25.
Solomon D, Breen N, McNeel T. Cervical Cancer Screening Rates and Potential Impact of Implementation of Screening Guidelines. CA Cancer J Clin 2007;57:105-111.
Castle PE, Stoler MH, Solomon D, Schiffman M. Relationship of biopsy-diagnosed cervical intraepithelial neoplasia grade 2 (CIN2) to the subsequent LEEP diagnosis. in press.
Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007;127:335-337.
Kreimer AR, Katki H, Schiffman M, Wheeler C, and Castle P for the ASCUS-LSIL Triage Study (ALTS) Group. Determinants of HPV persistence following LEEP treatment for cervical intraepithelial neoplasia grade 2 or 3. Journal of Infectious Diseases. Submitted.
Kreimer AR, Guido R, Solomon D, Schiffman M, Wacholder S, Jeronimo J, Wheeler C, and Castle P for the ASCUS-LSIL Triage Study (ALTS) Group. HPV testing following loop electrosurgical excision procedure (LEEP) identifies women at risk for post-treatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev, 2006; 15(5):908-14.
[Abstract in PubMed]
Foster K., Gynecologic cancers: Ovarian and cervical cancer prevention. SoCRA Source: Society of Clinical Research Associates, Issue 48, May, 2006. ISSN 1536-9900
Schiffman, Solomon. Summary of ALTS findings published to date. Arch Path Lab Med 2003;127:946-9.
[Abstract in PubMed]
Guido R, Schiffman M, Solomon, D, Burke, L for the ASCUS LSIL Triage Study (ALTS) Group. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: A two-year prospective study. Am J Obstet Gynecol. 2003;188:1405-5.
[Abstract in PubMed]
Cox JT, Schiffman M, Solomon, D for the ASCUS LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 and 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406-12.
[Abstract in PubMed]
ASCUS-LSIL Traige Study (ALTS) Group: A randomized trial on the management of Low-Grade Squamous Intraepithelial Lesion cytologic interpretations. Am J Obstet Gynecol. 2003;188:1393-1400.
[Abstract in PubMed]
ASCUS-LSIL Traige Study (ALTS) Group: Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003; 188: 1393-1400.
[Abstract in PubMed]
Cornelison TL, Montz FJ, Bristow RE, Chou B, Bovicelli A, Zeger SL. Decreased incidence of cervical cancer in Medicare-eligible California women. Obstet Gynecol 2002; 100(1):79-86.
[Abstract in PubMed]
Solomon D, Schiffman, Tarone. ASCUS LSIL Triage Study (ALTS) conclusions reaffirmed: response to a November 2001 commentary. Obstet Gynecol 2002;99:671-4.
[Abstract in PubMed]
Solomon D, Davey D Kurman R et al. The Bethesda System 2001: Terminology for Reporting the Results of Cervical Cytology. JAMA 2002;287:2114-2119.
[Abstract in PubMed]
Solomon D, Schiffman M, Tarone R. ASCUS LSIL Triage Study (ALTS) conclusions reaffirmed: Response to a November 2001 Commentary. Ob Gyn 2002;99:671-674.
[Abstract in PubMed]
Montz FJ, Farber FL, Bristow RE, Cornelison TL. Impact of increasing Papanicolaou test sensitivity and compliance: A modeled cost and outcomes analysis. Obstet Gynecol 2001; 97(5 Pt 1):781-8.
[Abstract in PubMed]
Sherman ME, Solomon D, Schiffman M: Qualification of ASCUS: a comparison of equivocal LSIL and Equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. Am J Clin Pathol 2001;116:386-394.
[Abstract in PubMed]
Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with Atypical Squamous Cells of Undetermined Significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299.
[Abstract in PubMed]
ALTS Group: Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
[Abstract in PubMed]
Cornelison TL. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment. Curr Opin Oncol 2000 Sep; 12(5):466-73. Review.
[Abstract in PubMed]
Back to Top
Ovarian Cancer Prevention
Huang L, Cronin K, Johnson KA, Mariotto A, and Feuer EJ: What can survival cure models tell us about population-based survival improvement in late stage colorectal, ovarian and testicular cancer? Cancer in press.
Foster, K., Gynecologic cancers: Ovarian and cervical cancer prevention. SoCRA Source: Society of Clinical Research Associates, Issue 48, May, 2006.
ISSN 1536-9900
Brewer MA, Johnson KA, Follen M, Gershenson D, Bast R Jr.: Prevention of Ovarian Cancer: Intraepithelial Neoplasia: Clin Cancer Research 2003; 9:20-30.
[Abstract in PubMed]
Cornelison TL, Natarajan N, Piver MS, Mettlin CJ: Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev 1997;21(1):1-6.
[Abstract in PubMed]
Back to Top
Other BGCRG Publications
Kelloff GJ, Sullivan DC, Baker H, et al.: Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 2007; 3:1-33.
Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano C, Cazzaniga M, Mora S, Gulisano M, Johansson H, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A: Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women. J Clin Oncol 2006; 24:129-135.
Mariotto AB, Wesley MN, Cronin KA, Johnson KA, Feuer EJ: Estimates of Long-Term Survival for Newly Diagnosed Cancer Patients. Cancer 2006; 106:2039-2050.
Muss HB, Hunter CP, Johnson KA,Eds, "Treatment and Management of Cancer in the Elderly", Basic and Clinical Oncology Series, Taylor and Francis Group, LLC; New York, 2006, ISBN: 0-8493-4035-7.
Percival SS, Johnson KA, Milner JA: "Opportunities and Challenges for Appropriate Nutrition of the Elderly Cancer Patient". In Muss HB, Hunter CP, Johnson KA, Eds., Treatment and Management of Cancer in the Elderly. New York: Taylor and Francis Group, 2006, 451-470.
Browne, D., "Medical Response to Injury from Ionizing Radiation" in Military Preventive Medicine: Mobilization and Deployment, Textbook of Military Medicine, Vol 1, 2003. p.655-667.
Keenan NL, Mark, Fugh-Berman A, Browne D, Kaczmarczyk J, and Hunter C. Severity of menopausal symptoms and use of both conventional and complementary/alternative therapies. Menopause 2003; 10: 507-515.
Trimble EL, Schoenfeldt M, Cornelison TL: Clinical trails referral resource. Current clinical trails in endometrial cancer, Oncology (Huntingt). 2003 Feb;17(2):238-40, 244, 249.
[Abstract in PubMed]
Trimble EL, Schoenfeldt M, Streicher H, Gius D, Cornelison TL: Clinical Trials Referral Resource. Clinical trials in cervical cancer. Oncology (Huntingt) 2003 Jan;17(1):84-9.
[Abstract in PubMed]
Trimble EL, Schoenfeldt M, Cornelison TL, Wright J, Kolker A, Christian M: Clinical trials referral resource. Clinical trials in ovarian cancer, Part 2. Oncology (Huntingt) 2002 Dec;16(12):1660-2, 1665-7.
[Abstract in PubMed]
Trimble EL, Schoenfeldt M, Cornelison TL, Wright J, Kolker A, Christian M: Clinical trials referral resource. Clinical trials in ovarian cancer; Part 1. Oncology (Huntingt) 2002 Nov;16(11):1498-9, 1504, 1506-7.
[Abstract in PubMed]
Mariotto A, Feuer EJ, Harlan LC, Wun L-M, Johnson KA, and Abrams J: Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975 - 1999. J of Natl Cancer Inst 2002 Nov 6 ;94 (21) :1626-1634.
[Abstract in PubMed]
Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF: Age, Gender, and Racial Differences in the Use of Standard Adjuvant Therapy for Colorectal Cancer. J Clin Oncol 2002; 20:1192-1202.
[Abstract in PubMed]
Anthony M, Johnson K: Roles of industry, government, and academia in SERM development. Ann N Y Acad Sci 2001; 949:315-316.
Kelloff GJ,Sigmon CC, Hawk ET, Johnson KA, Crowell JA, Guyton KZ: Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ; 2001; 154:13-26.
[Abstract in PubMed]
Kelloff GJ, Sigman CC, Johnson KA, Boone CW, Greenwald P, Crowell JA, Hawk ET, and Doody LA: Perspectives on surrogate Endpoints in the Development of Drugs that Reduce the Risk of Cancer. Cancer Epidemiol Biomark Prev, 2000; 9:127-137.
[Abstract in PubMed]
Johnson, Karen. "Cancer prevention in the elderly." In Cancer in the Elderly. Ed. Carrie P. Hunter, Karen A. Johnson, Hyman B. Muss, New York, NY: Marcel Dekker, Inc., 2000, pp. 57 - 68.
Cornelison TL, Trimble EL, Kosary CL: SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988 - 1994. Gynecologic Oncology 74, 350-355 (1999).
[Abstract in PubMed]
del Carmen MG, Montz FJ, Bristow RE, Bovicelli A, Cornelison T Trimble E: Ethnic differences in patterns of care of stage 1A(1) and stage 1A(2) cervical cancer: a SEER database study. Gynecol Oncol 1999 Oct;75(1):113-7.
[Abstract in PubMed]
Back to Top
Workshop Reports
June 29, 2002: Workshop Summary, HPV Immunology Workshop (pdf, 54kb) - DoubleTree Hotel Rockville, Maryland
March 31, 2000: Executive Summary, Ovarian Cancer Prevention Workshop - The Westin San Francisco Airport Hotel
Back to Top
